Correlations of the Microvascular Abnormalities on NVC (Nail Fold Video Capillaroscopy) and GAVE (Gastric Antral Vascular Ectasia) as Seen on EGD

NCT ID: NCT07127952

Last Updated: 2026-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-03

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to determine whether a procedure called capillaroscopy can help distinguish patients who are diagnosed with GAVE (gastric antral vascular ectasia) with an autoimmune disease versus idiopathic/other conditions based on EGD findings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary aim of this study is to define the prevalence and findings (as per quantification) of nail fold video capillaroscopy abnormalities in patients with GAVE. The secondary aim is to compare the findings of NVC and clinical presentation in patients with GAVE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Antral Vascular Ectasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GAVE without connective tissue disease

Will include patients between 18 and 95 seen at Mayo Clinic in Florida who were diagnosed with GAVE based on the EGD findings. Will include patients with GAVE without connective tissue disease Patient can be identified using slicer dicer or advanced text explorer and will be invited to have a nail fold video capillaroscopy.

Group Type OTHER

Video Capillaroscopy

Intervention Type DEVICE

A non-invasive imaging technique used to assess capillary structure and morphology in the nailfold area, commonly used in evaluating microvascular changes associated with connective tissue diseases.

GAVE with CTD

Will include patients between 18 and 95 years old seen at Mayo Clinic in Florida who were diagnosed with GAVE (Gastric antral vascular ectasia) based on the EGD findings. Will include patients with gave and connective tissue disease. Patient can be identified using slicer dicer or advanced text explorer and will be invited to have a nail fold video capillaroscopy.

Group Type OTHER

Video Capillaroscopy

Intervention Type DEVICE

A non-invasive imaging technique used to assess capillary structure and morphology in the nailfold area, commonly used in evaluating microvascular changes associated with connective tissue diseases.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Video Capillaroscopy

A non-invasive imaging technique used to assess capillary structure and morphology in the nailfold area, commonly used in evaluating microvascular changes associated with connective tissue diseases.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nailfold Video Capillaroscopy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years and older with gave diagnosis as pair EGD performed in Gastroenterology as standard of care.

Patients with GAVE with connective tissue disease will be compared to patients with GAVE without a connective tissue disease.

Exclusion Criteria

* Age less than 18 years of age, pregnant individuals, dialysis dependent, type 2 diabetes, recent hand trauma or manicure (\<2 weeks), routine use of vibratory tools, history of acrocyanosis or erythromelalgia, previous diagnosis of a bleeding disorder, diagnosis of psoriasis, diagnosis of anti-phospholipid syndrome, exposure to toluene or benzoyl, diagnosis of psoriasis, diagnosis of COPD.
Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Florentina Berianu

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Florentina Berianu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic (Florida)

Jacksonville, Florida, United States

Site Status

Mayo Clinic Health System-Eau Claire Clinic

Eau Claire, Wisconsin, United States

Site Status

Mayo Clinic Health Systems

Eau Claire, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

25-001900

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.